Investigation of SERPINE1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep vein thrombosis

Kardiologia Polska

Volumn 67, Issue 10, 2009, Pages 1088-1094

  Spiroski, Igor ^a   Kedev, Sashko ^a   Antov, Slobodan ^a   Trajkov, Dejan ^a   Petlichkovski, Aleksandar ^a   Dzhekova Stojkova, Sloboda ^a   Kostovska, Stojanka ^b   Spiroski, Mirko ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^b Institute of Transfusion Medicine   (Macedonia)

Author keywords

Deep venous thrombosis; Macedonians; Occlusive artery disease; SERPINE1 polymorphism

Indexed keywords

DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; MACEDONIA (REPUBLIC); MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

EID: 72249091882     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ginsburg D, Zeheb R, Yang AY, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-1680 (Pubitemid 17219532)
2. Schwartz CE, Stanislovitis P, Phelan MC, et al. Deletion mapping of plasminogen activator inhibitor, type I (PLANH1) and beta-glucuronidase (GUSB) in 7q21-q22. Cytogenet Cell Genet 1991; 56: 152-153
3. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745 (Pubitemid 23162248)
4. Eriksson P, Kallin B, van 't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855
5. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-156 (Pubitemid 28277590)
6. Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-1733
7. Fay WP, Parker AC, Condrey LR, et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-208
8. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231
9. Spiroski I, Kedev S, Antov S, et al. Association of methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR- 1298) genetic polymorphisms with occlusive artery disease and deep venous thrombosis in Macedonians. Croat Med J 2008; 49: 39-49. (Pubitemid 351346741)
10. Spiroski I, Kedev S, Antov S, et al. Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol 2008; 55: 587-594
11. Towner P. Purification of DNA. In: Brown TA (ed.). Essential molecular biology. Oxford University Press, Oxford. 1995; 47-54.
12. Spiroski M, Arsov T, Petlichkovski A, et al. Case study: Macedonian Human DNA Bank (hDNAMKD) as a source for public health genetics. In: Georgieva L, Burazeri G (eds.). Health Determinants in the Scope of New Public Health. Hans Jacobs Company Sofia, 2005; 33-44.
13. Mahfouz RA, Sabbagh AS, Shammaa DM, et al. Factor XIII gene V34L mutation in the Lebanese population: Another unique feature in this community? Mol Biol Rep 2008; 35: 375-378
14. Lancaster A, Nelson MP, Meyer D, et al. PyPop: a software framework for population genomics: analyzing large-scale multilocus genotype data. Pac Symp Biocomput 2003; 514-525
15. Lancaster AK, Single RM, Solberg OD, et al. PyPop update - a software pipeline for large-scale multilocus population genomics. Tissue Antigens 2007; 69 (Suppl. 1): 192-197
16. Single RM, Meyer D, Mack SJ, et al. 14th International HLA and Immunogenetics Workshop: report of progress in methodology, data collection, and analyses. Tissue Antigens 2007; 69 (Suppl. 1): 185-187 (Pubitemid 46625881)
17. Guo S, Thomson E. Performing the exact test of Hardy Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361.
18. Schneider S, Roessli D, Excoffier L. Arlequin version 2.000: a software for population genetics data analysis. Geneva (Switzerland): Genetics and Biometry Laboratory, University of Geneva; 2000.
19. Watterson GA. The homozygozity test of neutrality. Genetics 1978; 88: 405-417
20. Slatkin M, Excoffier L. Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Heredity 1996; 76: 377-383 (Pubitemid 126732633)
21. Slatkin M. An exact test for neutrality based on the Ewens sampling distribution. Genet Res 1994; 64: 71-74 (Pubitemid 24289480)
22. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet 2008; 60: 293-308.
23. Holm S. A simple sequentially rejective Bonferroni test procedure. Scand J Statist 1979; 6: 65-70.
24. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62. (Pubitemid 27029943)
25. Onalan O, Balta G, Oto A, et al. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 2008; 26: 211-217
26. Chen YL, Zhang JX, Wang PX, et al. Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005; 22: 624-627
27. Su S, Chen S, Zhao J, et al. Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 2006; 26: 948-954 (Pubitemid 43732177)
28. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27: 2250-2257 (Pubitemid 350287257)
29. Peck G, Smeeth L, Whittaker J, et al. The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults. PLoS ONE 2008; 3: e3691.
30. Martinez-Calatrava MJ, Martinez-Larrad MT, Zabena C, et al. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes Metab 2007; 9: 134-135 (Pubitemid 44921054)
31. Xu X, Li J, Sheng W, et al. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008; 26: 48-62. (Pubitemid 351931421)
32. Attia J, Thakkinstian A, Wang Y, et al. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis 2007; 16: 173-179 (Pubitemid 47048923)
33. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658 (Pubitemid 43289155)
34. Brogren H, Wallmark K, Jern S, et al. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism. Thromb Res 2008; 121: 793-797
35. Pare G, Serre D, Brisson D, et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am J Hum Genet 2007; 80: 673-682 (Pubitemid 46564404)
36. van Stralen KJ, Doggen CJ, Bezemer ID, et al. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol 2008; 28: 1872-1877